EULAR Sjögren's Syndrome Disease Activity Index (ESSDAI) is sensitive to show efficacy of rituximab treatment in a randomised controlled trial

Annals of the Rheumatic Diseases

Volumn 73, Issue 2, 2014, Pages 472-474

  Moerman, R V ^a   Arends, S ^a   Meiners, P M ^a   Brouwer, E ^a   Spijkervet, F K L ^a   Kroese, F G M ^a   Vissink, A ^a   Bootsma, H ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; RITUXIMAB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFECT; DRUG EFFICACY; EULAR SJOGREN SYNDROME DISEASE ACTIVITY INDEX; HUMAN; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; SCORING SYSTEM; SJOEGREN SYNDROME; TREATMENT OUTCOME; B CELLS; CONTROLLED CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; LETTER; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; SJÃGREN'S SYNDROME;

B CELLS; DISEASE ACTIVITY; SJÃGREN'S SYNDROME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; DOUBLE-BLIND METHOD; HUMANS; IMMUNOLOGIC FACTORS; SEVERITY OF ILLNESS INDEX; SJOGREN'S SYNDROME; TREATMENT OUTCOME;

EID: 84891737329     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2013-203736     Document Type: Article

References (7)

1. Meiners PM, Vissink A, Kallenberg CG, et al. Treatment of primary Sjögren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point? Expert Opin Biol Ther 2011;11:1381-94.
2. Ramos-Casals M, Tzioufas AG, Stone JH, et al. Treatment of primary Sjögren syndrome: a systematic review. JAMA 2010;304:452-60.
3. Seror R, Ravaud P, Bowman SJ, et al. EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome. Ann Rheum Dis 2010;69:1103-9.
4. Seror R, Mariette X, Bowman S, et al. Accurate detection of changes in disease activity in primary Sjögren's syndrome by the European League Against Rheumatism Sjögren's Syndrome Disease Activity Index. Arthritis Care Res (Hoboken) 2010;62:551-8.
5. Meiners PM, Arends S, Brouwer E, et al. Responsiveness of disease activity indices ESSPRI and ESSDAI in patients with primary Sjögren's syndrome treated with rituximab. Ann Rheum Dis 2012;71:1297-302.
6. Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjögren's syndrome: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62:960-8.
7. Husted JA, Cook RJ, Farewell VT, et al. Methods for assessing responsiveness: a critical review and recommendations. J Clin Epidemiol 2000;53:459-68. (Pubitemid 30254341)